Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Proliferation
Drug Resistance, Neoplasm
Humans
Melanoma
/ pathology
Mice
Mice, Inbred C57BL
Mutation
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins B-raf
/ genetics
Reactive Oxygen Species
/ therapeutic use
Vemurafenib
/ pharmacology
BRAF inhibitor
BRAFV600E
D4M.3A melanoma cells
ascorbate
cancer
malignant melanoma
vemurafenib
vitamin C
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
05 04 2022
05 04 2022
Historique:
received:
17
02
2022
revised:
25
03
2022
accepted:
01
04
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
High-dose ascorbate paradoxically acts as a pro-oxidant causing the formation of hydrogen peroxide in an oxygen dependent manner. Tumor cells (in particular melanoma cells) show an increased vulnerability to ascorbate induced reactive oxygen species (ROS). Therefore, high-dose ascorbate is a promising pharmacological approach to treating refractory melanomas, e.g., with secondary resistance to targeted BRAF inhibitor therapy. BRAF mutated melanoma cells were treated with ascorbate alone or in combination with the BRAF inhibitor vemurafenib. Viability, cell cycle, ROS production, and the protein levels of phospho-ERK1/2, GLUT-1 and HIF-1α were analyzed. To investigate the treatment in vivo, C57BL/6NCrl mice were subcutaneously injected with D4M.3A (Braf
Identifiants
pubmed: 35406796
pii: cells11071229
doi: 10.3390/cells11071229
pmc: PMC8997901
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Reactive Oxygen Species
0
Vemurafenib
207SMY3FQT
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cell Death Dis. 2017 Feb 2;8(2):e2594
pubmed: 28151482
Clin Cancer Res. 2017 Oct 15;23(20):6203-6214
pubmed: 28724666
Ann Intern Med. 2004 Apr 6;140(7):533-7
pubmed: 15068981
Cell. 2018 May 31;173(6):1413-1425.e14
pubmed: 29754815
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cancer Cell. 2013 Mar 18;23(3):302-15
pubmed: 23477830
Oncogene. 2012 Nov 22;31(47):4898-911
pubmed: 22286766
Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685-9
pubmed: 1068480
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9
pubmed: 18678913
Recent Prog Horm Res. 2001;56:127-55
pubmed: 11237210
Nature. 1980 Apr 17;284(5757):629-31
pubmed: 7366735
Dermatol Pract Concept. 2017 Apr 30;7(2):1-6
pubmed: 28515985
Cancer Cell. 2009 Jun 2;15(6):501-13
pubmed: 19477429
Clin Epigenetics. 2015 Apr 29;7:51
pubmed: 25977731
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9
pubmed: 16157892
Prostaglandins Leukot Essent Fatty Acids. 1988 Nov;34(2):119-26
pubmed: 3149408
Mol Cancer. 2017 Jun 8;16(1):102
pubmed: 28595656
Oncogene. 2014 Sep 18;33(38):4697-708
pubmed: 24681955
Nature. 2010 Dec 16;468(7326):973-7
pubmed: 21107323
J Am Coll Nutr. 2013;32(3):187-93
pubmed: 23885992
Antioxidants (Basel). 2018 Jul 12;7(7):
pubmed: 30002308
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Cancer Res. 2014 Oct 1;20(19):4994-5000
pubmed: 25096067
Cancer Discov. 2014 Apr;4(4):423-33
pubmed: 24469106
Oncotarget. 2013 Nov;4(11):1986-98
pubmed: 24161908
Cancer Cell. 2017 Apr 10;31(4):487-500.e8
pubmed: 28366679
J Immunol. 2013 Dec 15;191(12):5802-6
pubmed: 24227785
Science. 2015 Dec 11;350(6266):1391-6
pubmed: 26541605
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Curr Nutr Rep. 2020 Sep;9(3):226-235
pubmed: 32602055
Cell. 2012 Sep 14;150(6):1135-46
pubmed: 22980977
Lancet Oncol. 2018 Apr;19(4):510-520
pubmed: 29477665
Oncogene. 2020 Aug;39(32):5468-5478
pubmed: 32616888
Nature. 2010 Dec 16;468(7326):968-72
pubmed: 21107320
Eur J Cancer. 2017 Mar;73:93-101
pubmed: 28162869
Sci Transl Med. 2014 Feb 5;6(222):222ra18
pubmed: 24500406
J Cell Mol Med. 2014 Mar;18(3):530-41
pubmed: 24330097
Biol Cell. 2001 Sep;93(1-2):53-62
pubmed: 11730323
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Biochim Biophys Acta. 2016 Apr;1863(4):770-84
pubmed: 26844774
Blood. 2020 Sep 17;136(12):1394-1401
pubmed: 32730592
Sci Rep. 2018 Jan 12;8(1):587
pubmed: 29330434
Mol Carcinog. 2017 Aug;56(8):1965-1976
pubmed: 28370562
EBioMedicine. 2016 Jun;8:132-149
pubmed: 27428425
Free Radic Biol Med. 2015 Oct;87:193-203
pubmed: 26119785
J Biol Chem. 2017 Jul 14;292(28):11727-11739
pubmed: 28546431
Dermatol Ther (Heidelb). 2021 Jun;11(3):751-767
pubmed: 33866515
J Biol Chem. 2009 Nov 13;284(46):31532-40
pubmed: 19755417
Pigment Cell Melanoma Res. 2014 May;27(3):495-501
pubmed: 24460976
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8749-54
pubmed: 17502596
Dermatol Online J. 2020 Jul 15;26(7):
pubmed: 32898395
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Cancer. 2017 Mar;73:85-92
pubmed: 28169047
Melanoma Res. 2008 Apr;18(2):147-51
pubmed: 18337652
NPJ Precis Oncol. 2018 Jan 8;2(1):1
pubmed: 29872720
Free Radic Biol Med. 2009 Jul 1;47(1):32-40
pubmed: 19254759
Cancer Immunol Immunother. 2003 Nov;52(11):693-8
pubmed: 12827307
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Theranostics. 2019 Jun 9;9(15):4461-4473
pubmed: 31285773
Crit Rev Oncol Hematol. 2019 Jan;133:99-111
pubmed: 30661664